ProPhase Labs, Inc.

As of August 10, 2023, ProPhase Labs, Inc. is considered risky and overvalued due to its negative P/E ratio, poor returns on capital, and significant underperformance compared to peers and the S&P 500.

As of October 1, 2023, ProPhase Labs, Inc. is considered attractive due to its undervaluation with a P/E ratio of 12.5 and a P/B ratio of 1.8, outperforming peers like QuidelOrtho and Hologic, indicating strong potential for price appreciation.

As of October 1, 2023, there is not enough technical data for ProPhase Labs, Inc. to determine if it is bullish or bearish.

As of March 2022, the management team of ProPhase Labs, Inc. includes Mr. Ted Karkus as Chairman and CEO, along with independent directors Mr. Jason Barr, Dr. Louis Gleckel, and Mr. Warren Hirsch.

ProPhase Labs, Inc. manufactures and distributes homeopathic and healthcare products in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $1 million and a net loss of $5 million, with a market cap of $19.07 million.

As of Jun 18, ProPhase Labs, Inc. has a market capitalization of 19.07 million and reported net sales of 10.68 million with a net profit of -23.68 million over the last four quarters. Shareholder's funds are 7.35 million, and total assets amount to 63.20 million.